Freedom of Information request (FOI 22/1022)
Published 17 January 2024
© Crown copyright 2024
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-19-december-2022/freedom-of-information-request-foi-221022
20th December 2022
FOI 22/1022
Dear
Thank you for your reply, and apologies for the oversight, we were under the impression a response had been sent.
Our reference data team, have replied stating the following, there are no (market authorisations) MAs for any of these combinations.
The team have also double-checked if there have been any withdrawn or refused applications for the same list of products*, and have confirmed there are none.
Antipsychotic
Chlorpromazine + trifluoperazine + trihexyphenidyl
Chlorpromazine + trihexyphenidyl
Flupentixol + escitalopram
Flupentixol + melitracen
Haloperidol + trihexyphenidyl
Olanzapine + fluoxetine
Risperidone + trihexyphenidyl
Thioridazine + trihexyphenidyl
Thioridazine + trifluoperazine + trihexyphenidyl
Trifluoperazine + chlordiazepoxide
Trifluoperazine + chlordiazepoxide + trihexyphenidyl
Trifluoperazine + imipramine + chlordiazepoxide + trihexyphenidyl
Trifluoperazine + trihexyphenidyl
Antidepressant
Amitriptyline + chlordiazepoxide
Desvenlafaxine + clonazepam
Duloxetine + methylcobalamin
Duloxetine + pregabalin
Escitalopram + clonazepam
Escitalopram + etizolam
Escitalopram + L-methylfolate
Fluoxetine + alprazolam
Imipramine + alprazolam
Imipramine + chlordiazepoxide
Imipramine + diazepam
Paroxetine + clonazepam
Sertraline + alprazolam
Benzodiazepine/sedative
Alprazolam + mebeverine
Alprazolam + melatonin
Alprazolam + propranolol
Chlordiazepoxide + clidinium
Chlordiazepoxide + clidinium + dicyclomine
Chlordiazepoxide + clidinium + dicyclomine + rabeprazole
Chlordiazepoxide + clidinium + pantoprazole
Chlordiazepoxide + mebeverine
Clonazepam + propranolol
Diazepam + dicyclomine
Diazepam + magaldrate + oxyphenonium
Diazepam + propranolol
Etizolam + propranolol
Melatonin + zolpidem
If you disagree with how we have interpreted the Freedom of Information Act 2000 with regards to your request, you can ask for the decision to be reviewed. The review will be carried out by a senior member of the Agency who was not involved with the original decision.
If you have a query about the information provided, please reply to this email If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date you receive this response and addressed to: info@mhra.gov.uk.
If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our
handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:
Information Commissioner’s Office
Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF
Please remember to quote the reference number above in any future communications.
Kind regards,
HQA FOI Team